Episode Details

Canada’s drug approval process is dragging on — and it’s costing the country big time. While Health Canada’s initial reviews are speedy, the real delays come from complex, multi-step pricing negotiations with provinces and the pan-Canadian Pharmaceutical Alliance. This sluggishness is driving big pharma to skip Canada altogether, hurting innovation and investment. Experts say Canada should lean harder on trusted foreign regulators to fast-track approvals — especially for cancer and rare disease drugs. Meanwhile, the industry argues that focusing only on drug costs ignores the massive economic boost these companies bring, including high-skilled jobs and billions to GDP. Time to rethink how we get life-saving treatments to Canadians — faster.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/b9e73c6f60838d8f